Unique technology, Unique market
Xspray Pharma’s unique technology could improve the quality of life, and make it possible for more patients to access improved Protein Kinase Inhibitor (PKI) drugs for treatment of cancer.
-
Latest report
Interim Report Q2 2024 -
Subscribe
Get our latest press releases and reports
Press releases
Press release 2024-09-19
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
Regulatory press release 2024-08-07
Interim Report Second Quarter 2024
Regulatory press release 2024-07-26
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development
Regulatory press release 2024-07-09
Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose
Regulatory press release 2024-05-31
New number of shares and votes in Xspray Pharma after TO6
Xspray Pharma uses its innovative, patented technology to develop amorphous product candidates that are improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. Often the original companies have secondary patents that are based on the crystalline forms of the active substance. Since Xspray Pharma’s products are amorphous, they can be marketed as soon as the original companies’ drug substance patents expire. This is a unique opportunity for a favorable market establishment on a multi billion dollar market.
We see a large potential for our product portfolio. Our technology is compatible for most of the more than 80 US markeded protein kinase inhibitors. The company’s new porduct candidates are being developed in the same manner as the company´s initial product, Dasynoc (dasatinib). The process is reproducible and reduces the effective developing time for future products in our pipeline. This is an exciting time! Per Andersson, CEO